Drug Information

Drug General Information
Drug ID
D0T1IJ
Former ID
DAP001287
Drug Name
Oprelvekin
Synonyms
Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN)
Indication Severe thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] Approved [536361], [542002]
Therapeutic Class
Anticoagulants
Company
Wyeth Pharmaceuticals
Formula
C854H1411N253O235S2
CAS Number
CAS 145941-26-0
PubChem Substance ID
47206975
SuperDrug ATC ID
L03AC02
Target and Pathway
Target(s) Interleukin-11 receptor alpha chain Target Info Binder [536534]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
PANTHER Pathway Interleukin signaling pathway
WikiPathways Interleukin-11 Signaling Pathway
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 542002(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6971).
Ref 536534Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.